André M. Murad

2.4k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

André M. Murad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, André M. Murad has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in André M. Murad's work include Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (6 papers) and Lung Cancer Treatments and Mutations (5 papers). André M. Murad is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (6 papers) and Lung Cancer Treatments and Mutations (5 papers). André M. Murad collaborates with scholars based in Brazil, United States and Germany. André M. Murad's co-authors include Andy Petroianu, Marco Antônio Gonçalves Rodrigues, Flávia Ferretti Santiago, Paulo Roberto Savassi Rocha, Rodrigo C. Guimarães, Ronaldo de Albuquerque Ribeiro, Carlos H. Barrios, Mauro Zukin, Fernando Meton de Alencar Câmara Vieira and Luiz H. Araujo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

André M. Murad

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1993 638 citations André M. Murad, Flávia Ferretti Santiago et al. Cancer profile →

Peers

Countries citing papers authored by André M. Murad

Since Specialization

Citations

This map shows the geographic impact of André M. Murad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André M. Murad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André M. Murad more than expected).

Fields of papers citing papers by André M. Murad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André M. Murad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André M. Murad. The network helps show where André M. Murad may publish in the future.

Co-authorship network of co-authors of André M. Murad

This figure shows the co-authorship network connecting the top 25 collaborators of André M. Murad. A scholar is included among the top collaborators of André M. Murad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André M. Murad. André M. Murad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report 2023 ·Journal of Medical Case Reports ·Auro del Giglio, Beatriz da Costa Aguiar Alves, André M. Murad, Fernando Luiz Affonso Fonseca	0
2	Molecular Dynamics of Synthetic Flagelliform Silk Fiber Assembly 2022 ·Macromolecular Materials and Engineering ·Daniela Bittencourt, Paula Nunes de Oliveira, (unknown), Sônia Maria de Freitas, Luciano Paulino Silva, André M. Murad, (unknown), Randolph V. Lewis, Elíbio L. Rech	1
3	Molecular Dynamics of Synthetic Flagelliform Silk Fiber Assembly 2021 ·Macromolecular Materials and Engineering ·Daniela Bittencourt, Paula Nunes de Oliveira, (unknown), Sônia Maria de Freitas, Luciano Paulino Silva, André M. Murad, (unknown), Randolph V. Lewis, Elíbio L. Rech	1
4	Abstract 565: A single institutional experience with droplet digital polymerase chain reaction (ddPCR) liquid biopsy for therapeutic decision in avanced solid tumors 2021 ·Cancer Research ·André M. Murad	1
5	A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors. 2021 ·Journal of Clinical Oncology ·André M. Murad, (unknown), José Cláudio Casali da Rocha	2
6	A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors. 2020 ·Journal of Clinical Oncology ·André M. Murad, José Cláudio Casali da Rocha, (unknown)	1
7	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. 2015 ·Journal of Clinical Oncology ·David Cunningham, Niall C. Tebbutt, Ірина Давиденко, André M. Murad, Salah‐Eddin Al‐Batran, David H. Ilson, Sergei Tjulandin, Evgeny Gotovkin, Bogusława Karaszewska, Igor Bondarenko, Mohamedtaki Abdulaziz Tejani, Anghel Adrian Udrea, Mustapha Tehfé, Nigel Baker, Kelly S. Oliner, Yilong Zhang, Tien Hoang, Roger Sidhu, Daniel Virgil Thomas Catenacci	120
8	Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. 2014 ·PubMed ·N Yamaguchi, Ingrid A. Mayer, (unknown), (unknown), André M. Murad, Auro del Giglio, Venâncio Avancini Ferreira Alves	7
9	RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. 2013 ·Journal of Clinical Oncology ·David Cunningham, Salah‐Eddin Al‐Batran, Ірина Давиденко, David H. Ilson, André M. Murad, Niall C. Tebbutt, Yizhou Jiang, Elwyn Loh, Sarita Dubey, (unknown)	17
10	Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2 2013 ·Journal of Clinical Oncology ·Mauro Zukin, Carlos H. Barrios, José Rodrigues Pereira, Ronaldo de Albuquerque Ribeiro, (unknown), (unknown), André M. Murad, Fábio Franke, (unknown), Luiz H. Araujo, Clarissa Baldotto, Fernando Meton de Alencar Câmara Vieira, I. A. Small, Carlos Gil Ferreira, Rogério Lilenbaum	161
11	A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. 2012 ·Journal of Clinical Oncology ·Rogério Lilenbaum, Mauro Zukin, José Rodrigues Pereira, Carlos H. Barrios, Ronaldo de Albuquerque Ribeiro, (unknown), (unknown), André M. Murad, Fábio Franke, (unknown), Luiz H. Araujo, Clarissa Baldotto, Fernando Meton de Alencar Câmara Vieira, I. A. Small, Carlos Gil Ferreira	18
12	Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study 2010 ·Clinical Colorectal Cancer ·Antônio C. Buzaid, (unknown), (unknown), Sérgio D. Simon, Luis Fein, Jorge Hidalgo, André M. Murad, Regina Esser, Stefanie Senger, Guillermo Lerzo	10
13	Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen 2006 ·Gastric Cancer ·André M. Murad, (unknown), J. Vinholes, (unknown), (unknown), (unknown)	4
14	Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer 2003 ·American Journal of Clinical Oncology ·André M. Murad, Rodrigo C. Guimarães, (unknown), (unknown), (unknown), (unknown), (unknown)	22
15	Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer 2003 ·American Journal of Clinical Oncology ·André M. Murad, Rodrigo C. Guimarães, (unknown), (unknown), (unknown), (unknown), (unknown)	27
16	Phase II Trial of the Use of Paclitaxel and Gemcitabine as a Salvage Treatment in Metastatic Breast Cancer 2001 ·American Journal of Clinical Oncology ·André M. Murad, Rodrigo C. Guimarães, (unknown), (unknown), (unknown), (unknown)	38
17	Phase II Trial of the Combination of Paclitaxel and 5-Fluorouracil in the Treatment of Advanced Gastric Cancer 1999 ·American Journal of Clinical Oncology ·André M. Murad, Andy Petroianu, Rodrigo C. Guimarães, (unknown), (unknown), (unknown)	74
18	Chemotherapy for Advanced Gastric Cancer: Focus on New Agents and Combinations 1999 ·Cancer Control ·André M. Murad	4
19	Pharmacoeconomic Evaluation of Tegafur-Uracil (UFT) vs Fluorouracil for the Management of Colorectal Cancer in Brazil and Argentina 1997 ·Clinical Drug Investigation ·André M. Murad, (unknown), (unknown), Steven R. Arikian, John Doyle, Christopher M. Dezii, (unknown), (unknown)	9
20	Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer breakdown → 1993 ·Cancer ·André M. Murad, Flávia Ferretti Santiago, Andy Petroianu, Paulo Roberto Savassi Rocha, Marco Antônio Gonçalves Rodrigues, (unknown)	638

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact